Innate's first NK cell engager selected by Sanofi as drug candidate for development
IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody format Selection of IPH6101/SAR443579 triggers a €7M milestone payment to Innate Innate...Innate Pharma to participate in upcoming investor conferences
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the...Innate Pharma to return US and EU Lumoxiti commercialization rights to AstraZeneca
Innate will no longer pursue Lumoxiti commercialization activities in US or EU; Company to re-focus investments in its R&D portfolio Companies will develop a transition plan with the goal of returning...Innate Pharma to present additional efficacy data for monalizumab in combination with cetuximab in head and neck cancer at the ESMO immuno-oncology virtual congress
Phase 2 expansion cohort data supports ongoing Phase 3 trial Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will present...Innate Pharma 2021 financial calendar
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2021 financial calendar: March 18, 2021: Publication of 2020 financial...Innate Pharma reports third quarter 2020 financial results and business update
Lacutamab granted PRIME designation in Sézary Syndrome by the European Medicines Agency Monalizumab Phase 3 study initiated, triggering $50 million milestone payment Cash position of €163.6 million*...Innate Pharma receives PRIME designation from the European Medicines Agency for lacutamab in Sézary syndrome
Priority Medicines (PRIME) designation supports the potential for lacutamab to benefit Sézary Syndrome patients in need of new treatment options Innate Pharma SA (Euronext Paris: IPH – ISIN...Innate Pharma to participate in upcoming investor conferences
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that members of its senior management team are scheduled to participate in the...Innate Pharma launches HopeConnectLearn: a new online resource for hairy cell leukemia patients
New US website aims to educate and connect this rare disease community Rockville, Md., November 5, 2020, 8:00 AM EST Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) ("Innate"...First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca
Milestone payment further bolsters Innate’s cash position INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy and...
